News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major headlines emerged in the past hour, leaving markets largely quiet.
  • U.S. equity futures show little movement amid lack of news.
  • Treasury yields trade flat with no fresh macro data or Fed comments.
  • Oil and gold prices remain steady without new supply or demand catalysts.
  • Dollar index shows minimal change as investors await economic releases.

Latest Articles

Apogee CFO Disposes $180,000 in Stock as Shares Trade Near Yearly High

Apogee CFO Disposes $180,000 in Stock as Shares Trade Near Yearly High

Apogee Therapeutics CFO Jane Henderson sold 2,000 shares on April 16, 2026, for $90.00 per share, generating $180,000 in proceeds. The transaction was executed through a Rule 10b5-1 trading plan. The stock has climbed roughly 178% over the past year and sits close to its 52-week high. Apogee also completed a $403 million underwritten offering and p…

StandardAero CFO Disposes $63,092 in Stock After Near-Term Purchase

StandardAero CFO Disposes $63,092 in Stock After Near-Term Purchase

StandardAero finance chief Daniel Satterfield reported a sale of 2,306 common shares on April 16, 2026, at $27.36 per share for $63,092, one day after acquiring 8,538 shares. The company recently posted record fourth-quarter 2025 results and has drawn varied analyst attention, while investing-platform commentary flags the stock as undervalued.

Revolution Medicines CEO Executes Large Share Sale Amid Major Capital Raise and Positive Phase III Readout

Revolution Medicines CEO Executes Large Share Sale Amid Major Capital Raise and Positive Phase III Readout

Revolution Medicines' CEO Mark A. Goldsmith sold 120,000 shares on April 15, 2026, realizing $18,010,488 at $150.0874 per share and simultaneously exercised 120,000 options. The transactions leave him with both direct and indirect holdings, while the company completed about $2.1 billion in concurrent equity and convertible note offerings and disclo…

Arista Networks Director Wassenaar Sells $213,532 in Stock

Arista Networks Director Wassenaar Sells $213,532 in Stock

Yvonne Wassenaar, a member of Arista Networks Inc's board, sold 1,395 shares on April 15, 2026, for a total of $213,532 under a pre-established Rule 10b5-1 plan. The sales were executed at prices between $151.0697 and $154.72. After the trades, Wassenaar retains direct ownership of 9,784 shares. The move comes amid a wave of positive analyst commen…

Ionis Director Executes $381K Sale as Analysts Focus on Tryngolza Progress

Ionis Director Executes $381K Sale as Analysts Focus on Tryngolza Progress

Lynne Parshall, a director at Ionis Pharmaceuticals (IONS), sold 5,000 shares on April 15, 2026, in two transactions totaling $381,366 under a Rule 10b5-1 plan adopted May 6, 2025. The disposals come as the stock has risen 167% over the past year and ahead of an April 29 earnings report. Multiple analyst actions and a new pricing strategy for Tryng…

Photronics Director Disposes $451K in Shares as Stock Nears 52-Week High

Photronics Director Disposes $451K in Shares as Stock Nears 52-Week High

Photronics director Lee Kang Jyh sold 10,000 shares on April 15, 2026, for $45.1 each, netting $451,000 and leaving him with 375,850 shares. The trade occurred while PLAB shares traded at $48.38, close to a 52-week peak, after a 174% year-over-year gain. Separately, Photronics reported fiscal Q1 2026 results above expectations, saw a price-target l…